Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Alzheimer is a progressive neurologic disorder beginning with mild memory loss. It could possibly lead to a loss of the ability to carry on a conversation and respond to the environment.

The Alzheimer pipeline market research report provides comprehensive information about the Alzheimer pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Alzheimer Pipeline Products Market Segmentation by Territories

Some of the key territories with Alzheimer products in the pipeline are the United States, Europe, Global, Australia, China, Canada, the United Kingdom, and South Korea among others. As of November 2022, the US has the highest number of products in the pipeline out of them all.

Alzheimer Pipeline Products Market Analysis, by Territories, 2022 (%)

Alzheimer Pipeline Products Market Analysis, by Territories

For more territory insights into the Alzheimer pipeline products market, download a free report sample

Alzheimer Pipeline Products Market Segmentation by Regulatory Paths

Some of the key regulatory paths followed by the Alzheimer pipeline products market are 510(k), CE-IVD, NMPA, TGA, MDL, PMA, UKCA, and MDITAC among others. Most of the products follow the 510(k) pathway to enter the market.

Alzheimer Pipeline Products Market Analysis, by Regulatory Paths, 2022 (%)

Alzheimer Pipeline Products Market Analysis, by Regulatory PathsFor more Alzheimer pipeline products regulatory path insights, download a free report sample

Alzheimer Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Alzheimer pipeline products market are 5M Biomed LLC, AC Immune SA, Acobiom, Acumen Pharmaceuticals Inc, Biomedical Development Corp, BioSystems International, Boston University Medical Campus, Johns Hopkins University School of Medicine, Johns Hopkins University, The Florey Institute of Neuroscience and Mental Health, and Brigham and Women’s Hospital among others.

Alzheimer Pipeline Products Market Report Overview

Key Territories The United States, Europe, Global, Australia, China, Canada, United Kingdom, and South Korea
Analysis Year 2022
Key Regulatory Paths 510(k), CE-IVD, NMPA, TGA, MDL, PMA, UKCA, and MDITAC
Leading Companies 5M Biomed LLC, AC Immune SA, Acobiom, Acumen Pharmaceuticals Inc, Biomedical Development Corp, BioSystems International, Boston University Medical Campus, Johns Hopkins University School of Medicine, Johns Hopkins University, The Florey Institute of Neuroscience and Mental Health, and Brigham and Women’s Hospital

Alzheimer Pipeline Products Market Territories Outlook (2022)

  • The United States
  • Europe
  • Global
  • Australia
  • China
  • Canada
  • United Kingdom
  • South Korea

Alzheimer Pipeline Products Market Regulatory Paths Outlook (2022)

  • 510(k)
  • CE-IVD
  • NMPA
  • TGA
  • MDL
  • PMA
  • UKCA
  • MDITAC

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.
  • Identify emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Identify and understand important and diverse types of Alzheimer under development.
  • Develop market-entry and market-expansion strategies.
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
  • In-depth analysis of the product’s current stage of development, territory, and estimated launch date.

5M Biomed LLC
AC Immune SA
Acobiom
Acumen Pharmaceuticals Inc
Adlyfe Inc
Admit Therapeutics SL
ADx NeuroSciences NV
Aelan Cell Technologies
Agent Biotech
Albert Ludwigs University of Freiburg
Alere Inc
AltPep Corp
Alzheon Inc
Alzhyme Pty Ltd
Alzinova AB
Amarantus Bioscience Holdings Inc
Amarantus Diagnostics Inc
Ambergen Inc
Amco International Manufacturing Inc.
Amoneta Diagnostics SAS
Amprion Inc
Applied NeuroSolutions, Inc. (Inactive)
Arkley Biotek LLC
Ascent Bio-Nano Technologies Inc
attyloid GmbH
Banyan Biomarkers Inc
Beaumont Health System
BioArctic AB
Bioasis Technologies Inc
Biocross SL
Biois Corp
Biomedical Development Corp
BioSystems International
Boston University Medical Campus
Brigham and Women's Hospital
C2N Diagnostics LLC
Calviri Inc
Cassava Sciences Inc
Cayman Chemical Co
Chronix Biomedical Inc
Cleveland Diagnostics Inc.
Cognext Diagnostics LLC
Columbia University
Cx Precision Medicine Inc
Cymedx
Cytox Ltd
Diadem SRL
DiamiR LLC
DiaPat GmbH
Durin Technologies, Inc.
Early Alzheimer's Diagnostics LLC
Emory University
Eurobio Scientific SA
Florida Institute of Technology
French National Institute of Health and Medical Research
Fujirebio Diagnostics Inc
GenoScreen SAS
Ghent University
IBM Research-Australia
ICDD-sas
Inbiomed
Innovative Health Diagnostics
Inscopix Inc
Instituto de Estructura de la Materia
Integrated Diagnostics Inc (Inactive)
Intelligent OMICS Ltd
Janssen Pharmaceutica NV
Johns Hopkins University
Johns Hopkins University School of Medicine
KineMed Inc
King's College London
Lund University
McGill University Health Center
Medifron DBT Inc
Memory Dx LLC
Meso Scale Diagnostics LLC
Metabolon Inc
Michigan State University
MYND Diagnostics Ltd
Myriad RBM Inc
NanoSomiX Inc
Nanosphere Inc (Inactive)
National Research Foundation of Korea
National University of Singapore
Navotavo Inc
Nel ASA
NeoNeuro SAS
Neuro Bio Ltd
NeuroQuest Ltd
NeuroVision Imaging LLC
Newcastle University
Novel Bio-spectrum Technologies Inc (Inactive)
Numares AG
Oligomerix inc
Orasi Medical, Inc. (Inactive)
Oryzon Genomics SA
Peri Rx Inc
Pre Diagnostics AS
Predemtec GmbH
ProMIS Neurosciences Inc
Proplex Technologies Llc
Protagen AG
Proteome Sciences Plc
Proteomics International Laboratories Ltd
Quanterix Corp
Redox Diagnostics LLC
Roche Diagnostics GmbH
Roche Diagnostics International Ltd
Rockefeller University
Ruhr-University Bochum
Scanogen Inc
Scout Diagnostics LLC
Seer Biosciences Inc
Siemens Healthineers AG
Spanish National Research Council
StageZero Life Sciences Ltd
Sugentech Inc
Synaptogenix, Inc.
TauRx Pharmaceuticals Ltd
Telo Genomics Corp
The Florey Institute of Neuroscience and Mental Health
The Hong Kong University of Science and Technology
The University of Nottingham
Todos Medical
TopoGEN Inc
Trinity College Dublin
University of Calgary
University of California San Francisco
University of Chicago
University of Georgia
University of Gottingen
University of Illinois at Chicago
University of Luxembourg
University of Maryland Baltimore
University of Melbourne
University of Oxford
University of Pittsburgh
University of South Carolina
University of South Florida
University of Texas Health Science Center at Houston
University of Texas Southwestern Medical Center
Urvogelbio Pvt Ltd
US Biomarkers Inc
vall d hebron institut de Recerca
Veravas Inc
Virtici LLC
Vitruvian Biomedical Inc
Washington University in St Louis
Washington University School of Medicine
WellSIM Biomedical Technologies Inc
Zoiray Technologies Inc.

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 11

|1.2 List of Figures 22

2 Introduction 23

2.1 Alzheimer Overview 23

3 Products under Development 24

3.1 Alzheimer – Pipeline Products by Stage of Development 24

3.2 Alzheimer – Pipeline Products by Territory 25

3.3 Alzheimer – Pipeline Products by Regulatory Path 26

3.4 Alzheimer – Pipeline Products by Estimated Approval Date 27

3.5 Alzheimer – Ongoing Clinical Trials 28

4 Alzheimer – Pipeline Products under Development by Companies 29

4.1 Alzheimer Companies – Pipeline Products by Stage of Development 29

4.2 Alzheimer – Pipeline Products by Stage of Development 35

5 Alzheimer Companies and Product Overview 40

5.1 5M Biomed LLC Company Overview 40

5.1.1 5M Biomed LLC Pipeline Products & Ongoing Clinical Trials Overview 40

5.2 AC Immune SA Company Overview 41

5.2.1 AC Immune SA Pipeline Products & Ongoing Clinical Trials Overview 41

5.3 Acobiom Company Overview 43

5.3.1 Acobiom Pipeline Products & Ongoing Clinical Trials Overview 43

5.4 Acumen Pharmaceuticals Inc Company Overview 45

5.4.1 Acumen Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 45

5.5 Adlyfe Inc Company Overview 46

5.5.1 Adlyfe Inc Pipeline Products & Ongoing Clinical Trials Overview 46

5.6 Admit Therapeutics SL Company Overview 47

5.6.1 Admit Therapeutics SL Pipeline Products & Ongoing Clinical Trials Overview 47

5.7 ADx NeuroSciences NV Company Overview 48

5.7.1 ADx NeuroSciences NV Pipeline Products & Ongoing Clinical Trials Overview 48

5.8 Aelan Cell Technologies Company Overview 55

5.8.1 Aelan Cell Technologies Pipeline Products & Ongoing Clinical Trials Overview 55

5.9 Agent Biotech Company Overview 56

5.9.1 Agent Biotech Pipeline Products & Ongoing Clinical Trials Overview 56

5.10 Albert Ludwigs University of Freiburg Company Overview 59

5.10.1 Albert Ludwigs University of Freiburg Pipeline Products & Ongoing Clinical Trials Overview 59

5.11 Alere Inc Company Overview 60

5.11.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 60

5.12 AltPep Corp Company Overview 61

5.12.1 AltPep Corp Pipeline Products & Ongoing Clinical Trials Overview 61

5.13 Alzheon Inc Company Overview 62

5.13.1 Alzheon Inc Pipeline Products & Ongoing Clinical Trials Overview 62

5.14 Alzhyme Pty Ltd Company Overview 63

5.14.1 Alzhyme Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

5.15 Alzinova AB Company Overview 64

5.15.1 Alzinova AB Pipeline Products & Ongoing Clinical Trials Overview 64

5.16 Amarantus Bioscience Holdings Inc Company Overview 65

5.16.1 Amarantus Bioscience Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 65

5.17 Amarantus Diagnostics Inc Company Overview 66

5.17.1 Amarantus Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 66

5.18 Ambergen Inc Company Overview 67

5.18.1 Ambergen Inc Pipeline Products & Ongoing Clinical Trials Overview 67

5.19 Amco International Manufacturing Inc. Company Overview 68

5.19.1 Amco International Manufacturing Inc. Pipeline Products & Ongoing Clinical Trials Overview 68

5.20 Amoneta Diagnostics SAS Company Overview 69

5.20.1 Amoneta Diagnostics SAS Pipeline Products & Ongoing Clinical Trials Overview 69

5.21 Amprion Inc Company Overview 70

5.21.1 Amprion Inc Pipeline Products & Ongoing Clinical Trials Overview 70

5.22 Applied NeuroSolutions, Inc. (Inactive) Company Overview 71

5.22.1 Applied NeuroSolutions, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 71

5.23 Arkley Biotek LLC Company Overview 72

5.23.1 Arkley Biotek LLC Pipeline Products & Ongoing Clinical Trials Overview 72

5.24 Ascent Bio-Nano Technologies Inc Company Overview 73

5.24.1 Ascent Bio-Nano Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 73

5.25 attyloid GmbH Company Overview 74

5.25.1 attyloid GmbH Pipeline Products & Ongoing Clinical Trials Overview 74

5.26 Banyan Biomarkers Inc Company Overview 75

5.26.1 Banyan Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 75

5.27 Beaumont Health System Company Overview 76

5.27.1 Beaumont Health System Pipeline Products & Ongoing Clinical Trials Overview 76

5.28 BioArctic AB Company Overview 77

5.28.1 BioArctic AB Pipeline Products & Ongoing Clinical Trials Overview 77

5.29 Bioasis Technologies Inc Company Overview 78

5.29.1 Bioasis Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 78

5.30 Biocross SL Company Overview 79

5.30.1 Biocross SL Pipeline Products & Ongoing Clinical Trials Overview 79

5.31 Biois Corp Company Overview 84

5.31.1 Biois Corp Pipeline Products & Ongoing Clinical Trials Overview 84

5.32 Biomedical Development Corp Company Overview 85

5.32.1 Biomedical Development Corp Pipeline Products & Ongoing Clinical Trials Overview 85

5.33 BioSystems International Company Overview 86

5.33.1 BioSystems International Pipeline Products & Ongoing Clinical Trials Overview 86

5.34 Boston University Medical Campus Company Overview 87

5.34.1 Boston University Medical Campus Pipeline Products & Ongoing Clinical Trials Overview 87

5.35 Brigham and Women’s Hospital Company Overview 88

5.35.1 Brigham and Women’s Hospital Pipeline Products & Ongoing Clinical Trials Overview 88

5.36 C2N Diagnostics LLC Company Overview 89

5.36.1 C2N Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 89

5.37 Calviri Inc Company Overview 93

5.37.1 Calviri Inc Pipeline Products & Ongoing Clinical Trials Overview 93

5.38 Cassava Sciences Inc Company Overview 94

5.38.1 Cassava Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 94

5.39 Cayman Chemical Co Company Overview 97

5.39.1 Cayman Chemical Co Pipeline Products & Ongoing Clinical Trials Overview 97

5.40 Chronix Biomedical Inc Company Overview 98

5.40.1 Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 98

5.41 Cleveland Diagnostics Inc. Company Overview 99

5.41.1 Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 99

5.42 Cognext Diagnostics LLC Company Overview 100

5.42.1 Cognext Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 100

5.43 Columbia University Company Overview 101

5.43.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 101

5.44 Cx Precision Medicine Inc Company Overview 102

5.44.1 Cx Precision Medicine Inc Pipeline Products & Ongoing Clinical Trials Overview 102

5.45 Cymedx Company Overview 105

5.45.1 Cymedx Pipeline Products & Ongoing Clinical Trials Overview 105

5.46 Cytox Ltd Company Overview 106

5.46.1 Cytox Ltd Pipeline Products & Ongoing Clinical Trials Overview 106

5.47 Diadem SRL Company Overview 109

5.47.1 Diadem SRL Pipeline Products & Ongoing Clinical Trials Overview 109

5.48 DiamiR LLC Company Overview 111

5.48.1 DiamiR LLC Pipeline Products & Ongoing Clinical Trials Overview 111

5.49 DiaPat GmbH Company Overview 112

5.49.1 DiaPat GmbH Pipeline Products & Ongoing Clinical Trials Overview 112

5.50 Durin Technologies, Inc. Company Overview 113

5.50.1 Durin Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 113

5.51 Early Alzheimer’s Diagnostics LLC Company Overview 114

5.51.1 Early Alzheimer’s Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 114

5.52 Emory University Company Overview 115

5.52.1 Emory University Pipeline Products & Ongoing Clinical Trials Overview 115

5.53 Eurobio Scientific SA Company Overview 116

5.53.1 Eurobio Scientific SA Pipeline Products & Ongoing Clinical Trials Overview 116

5.54 Florida Institute of Technology Company Overview 117

5.54.1 Florida Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 117

5.55 French National Institute of Health and Medical Research Company Overview 118

5.55.1 French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 118

5.56 Fujirebio Diagnostics Inc Company Overview 119

5.56.1 Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 119

5.57 GenoScreen SAS Company Overview 122

5.57.1 GenoScreen SAS Pipeline Products & Ongoing Clinical Trials Overview 122

5.58 Ghent University Company Overview 123

5.58.1 Ghent University Pipeline Products & Ongoing Clinical Trials Overview 123

5.59 IBM Research-Australia Company Overview 124

5.59.1 IBM Research-Australia Pipeline Products & Ongoing Clinical Trials Overview 124

5.60 ICDD-sas Company Overview 125

5.60.1 ICDD-sas Pipeline Products & Ongoing Clinical Trials Overview 125

5.61 Inbiomed Company Overview 127

5.61.1 Inbiomed Pipeline Products & Ongoing Clinical Trials Overview 127

5.62 Innovative Health Diagnostics Company Overview 128

5.62.1 Innovative Health Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 128

5.63 Inscopix Inc Company Overview 129

5.63.1 Inscopix Inc Pipeline Products & Ongoing Clinical Trials Overview 129

5.64 Instituto de Estructura de la Materia Company Overview 130

5.64.1 Instituto de Estructura de la Materia Pipeline Products & Ongoing Clinical Trials Overview 130

5.65 Integrated Diagnostics Inc (Inactive) Company Overview 131

5.65.1 Integrated Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 131

5.66 Intelligent OMICS Ltd Company Overview 132

5.66.1 Intelligent OMICS Ltd Pipeline Products & Ongoing Clinical Trials Overview 132

5.67 Janssen Pharmaceutica NV Company Overview 133

5.67.1 Janssen Pharmaceutica NV Pipeline Products & Ongoing Clinical Trials Overview 133

5.68 Johns Hopkins University Company Overview 134

5.68.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 134

5.69 Johns Hopkins University School of Medicine Company Overview 135

5.69.1 Johns Hopkins University School of Medicine Pipeline Products & Ongoing Clinical Trials Overview 135

5.70 KineMed Inc Company Overview 136

5.70.1 KineMed Inc Pipeline Products & Ongoing Clinical Trials Overview 136

5.71 King’s College London Company Overview 137

5.71.1 King’s College London Pipeline Products & Ongoing Clinical Trials Overview 137

5.72 Lund University Company Overview 138

5.72.1 Lund University Pipeline Products & Ongoing Clinical Trials Overview 138

5.73 McGill University Health Center Company Overview 140

5.73.1 McGill University Health Center Pipeline Products & Ongoing Clinical Trials Overview 140

5.74 Medifron DBT Inc Company Overview 141

5.74.1 Medifron DBT Inc Pipeline Products & Ongoing Clinical Trials Overview 141

5.75 Memory Dx LLC Company Overview 142

5.75.1 Memory Dx LLC Pipeline Products & Ongoing Clinical Trials Overview 142

5.76 Meso Scale Diagnostics LLC Company Overview 143

5.76.1 Meso Scale Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 143

5.77 Metabolon Inc Company Overview 144

5.77.1 Metabolon Inc Pipeline Products & Ongoing Clinical Trials Overview 144

5.78 Michigan State University Company Overview 145

5.78.1 Michigan State University Pipeline Products & Ongoing Clinical Trials Overview 145

5.79 MYND Diagnostics Ltd Company Overview 146

5.79.1 MYND Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 146

5.80 Myriad RBM Inc Company Overview 147

5.80.1 Myriad RBM Inc Pipeline Products & Ongoing Clinical Trials Overview 147

5.81 NanoSomiX Inc Company Overview 148

5.81.1 NanoSomiX Inc Pipeline Products & Ongoing Clinical Trials Overview 148

5.82 Nanosphere Inc (Inactive) Company Overview 150

5.82.1 Nanosphere Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 150

5.83 National Research Foundation of Korea Company Overview 151

5.83.1 National Research Foundation of Korea Pipeline Products & Ongoing Clinical Trials Overview 151

5.84 National University of Singapore Company Overview 152

5.84.1 National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 152

5.85 Navotavo Inc Company Overview 153

5.85.1 Navotavo Inc Pipeline Products & Ongoing Clinical Trials Overview 153

5.86 Nel ASA Company Overview 154

5.86.1 Nel ASA Pipeline Products & Ongoing Clinical Trials Overview 154

5.87 NeoNeuro SAS Company Overview 156

5.87.1 NeoNeuro SAS Pipeline Products & Ongoing Clinical Trials Overview 156

5.88 Neuro Bio Ltd Company Overview 157

5.88.1 Neuro Bio Ltd Pipeline Products & Ongoing Clinical Trials Overview 157

5.89 NeuroQuest Ltd Company Overview 158

5.89.1 NeuroQuest Ltd Pipeline Products & Ongoing Clinical Trials Overview 158

5.90 NeuroVision Imaging LLC Company Overview 159

5.90.1 NeuroVision Imaging LLC Pipeline Products & Ongoing Clinical Trials Overview 159

5.91 Newcastle University Company Overview 160

5.91.1 Newcastle University Pipeline Products & Ongoing Clinical Trials Overview 160

5.92 Novel Bio-spectrum Technologies Inc (Inactive) Company Overview 161

5.92.1 Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 161

5.93 Numares AG Company Overview 162

5.93.1 Numares AG Pipeline Products & Ongoing Clinical Trials Overview 162

5.94 Oligomerix inc Company Overview 163

5.94.1 Oligomerix inc Pipeline Products & Ongoing Clinical Trials Overview 163

5.95 Orasi Medical, Inc. (Inactive) Company Overview 164

5.95.1 Orasi Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 164

5.96 Oryzon Genomics SA Company Overview 165

5.96.1 Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview 165

5.97 Peri Rx Inc Company Overview 167

5.97.1 Peri Rx Inc Pipeline Products & Ongoing Clinical Trials Overview 167

5.98 Pre Diagnostics AS Company Overview 168

5.98.1 Pre Diagnostics AS Pipeline Products & Ongoing Clinical Trials Overview 168

5.99 Predemtec GmbH Company Overview 169

5.99.1 Predemtec GmbH Pipeline Products & Ongoing Clinical Trials Overview 169

5.100 ProMIS Neurosciences Inc Company Overview 170

5.100.1 ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 170

5.101 Proplex Technologies Llc Company Overview 173

5.101.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 173

5.102 Protagen AG Company Overview 174

5.102.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 174

5.103 Proteome Sciences Plc Company Overview 175

5.103.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 175

5.104 Proteomics International Laboratories Ltd Company Overview 178

5.104.1 Proteomics International Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview 178

5.105 Quanterix Corp Company Overview 179

5.105.1 Quanterix Corp Pipeline Products & Ongoing Clinical Trials Overview 179

5.106 Redox Diagnostics LLC Company Overview 183

5.106.1 Redox Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 183

5.107 Roche Diagnostics GmbH Company Overview 184

5.107.1 Roche Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 184

5.108 Roche Diagnostics International Ltd Company Overview 185

5.108.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 185

5.109 Rockefeller University Company Overview 188

5.109.1 Rockefeller University Pipeline Products & Ongoing Clinical Trials Overview 188

5.110 Ruhr-University Bochum Company Overview 189

5.110.1 Ruhr-University Bochum Pipeline Products & Ongoing Clinical Trials Overview 189

5.111 Scanogen Inc Company Overview 190

5.111.1 Scanogen Inc Pipeline Products & Ongoing Clinical Trials Overview 190

5.112 Scout Diagnostics LLC Company Overview 191

5.112.1 Scout Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 191

5.113 Seer Biosciences Inc Company Overview 192

5.113.1 Seer Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 192

5.114 Siemens Healthineers AG Company Overview 193

5.114.1 Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview 193

5.115 Spanish National Research Council Company Overview 195

5.115.1 Spanish National Research Council Pipeline Products & Ongoing Clinical Trials Overview 195

5.116 StageZero Life Sciences Ltd Company Overview 196

5.116.1 StageZero Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 196

5.117 Sugentech Inc Company Overview 197

5.117.1 Sugentech Inc Pipeline Products & Ongoing Clinical Trials Overview 197

5.118 Synaptogenix, Inc. Company Overview 198

5.118.1 Synaptogenix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 198

5.119 TauRx Pharmaceuticals Ltd Company Overview 199

5.119.1 TauRx Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview 199

5.120 Telo Genomics Corp Company Overview 200

5.120.1 Telo Genomics Corp Pipeline Products & Ongoing Clinical Trials Overview 200

5.121 The Florey Institute of Neuroscience and Mental Health Company Overview 201

5.121.1 The Florey Institute of Neuroscience and Mental Health Pipeline Products & Ongoing Clinical Trials Overview 201

5.122 The Hong Kong University of Science and Technology Company Overview 202

5.122.1 The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 202

5.123 The University of Nottingham Company Overview 203

5.123.1 The University of Nottingham Pipeline Products & Ongoing Clinical Trials Overview 203

5.124 Todos Medical Company Overview 204

5.124.1 Todos Medical Pipeline Products & Ongoing Clinical Trials Overview 204

5.125 TopoGEN Inc Company Overview 207

5.125.1 TopoGEN Inc Pipeline Products & Ongoing Clinical Trials Overview 207

5.126 Trinity College Dublin Company Overview 208

5.126.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 208

5.127 University of Calgary Company Overview 209

5.127.1 University of Calgary Pipeline Products & Ongoing Clinical Trials Overview 209

5.128 University of California San Francisco Company Overview 210

5.128.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 210

5.129 University of Chicago Company Overview 211

5.129.1 University of Chicago Pipeline Products & Ongoing Clinical Trials Overview 211

5.130 University of Georgia Company Overview 212

5.130.1 University of Georgia Pipeline Products & Ongoing Clinical Trials Overview 212

5.131 University of Gottingen Company Overview 213

5.131.1 University of Gottingen Pipeline Products & Ongoing Clinical Trials Overview 213

5.132 University of Illinois at Chicago Company Overview 215

5.132.1 University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 215

5.133 University of Luxembourg Company Overview 217

5.133.1 University of Luxembourg Pipeline Products & Ongoing Clinical Trials Overview 217

5.134 University of Maryland Baltimore Company Overview 218

5.134.1 University of Maryland Baltimore Pipeline Products & Ongoing Clinical Trials Overview 218

5.135 University of Melbourne Company Overview 219

5.135.1 University of Melbourne Pipeline Products & Ongoing Clinical Trials Overview 219

5.136 University of Oxford Company Overview 220

5.136.1 University of Oxford Pipeline Products & Ongoing Clinical Trials Overview 220

5.137 University of Pittsburgh Company Overview 221

5.137.1 University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 221

5.138 University of South Carolina Company Overview 222

5.138.1 University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 222

5.139 University of South Florida Company Overview 223

5.139.1 University of South Florida Pipeline Products & Ongoing Clinical Trials Overview 223

5.140 University of Texas Health Science Center at Houston Company Overview 225

5.140.1 University of Texas Health Science Center at Houston Pipeline Products & Ongoing Clinical Trials Overview 225

5.141 University of Texas Southwestern Medical Center Company Overview 226

5.141.1 University of Texas Southwestern Medical Center Pipeline Products & Ongoing Clinical Trials Overview 226

5.142 Urvogelbio Pvt Ltd Company Overview 227

5.142.1 Urvogelbio Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 227

5.143 US Biomarkers Inc Company Overview 228

5.143.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 228

5.144 vall d hebron institut de Recerca Company Overview 229

5.144.1 vall d hebron institut de Recerca Pipeline Products & Ongoing Clinical Trials Overview 229

5.145 Veravas Inc Company Overview 230

5.145.1 Veravas Inc Pipeline Products & Ongoing Clinical Trials Overview 230

5.146 Virtici LLC Company Overview 231

5.146.1 Virtici LLC Pipeline Products & Ongoing Clinical Trials Overview 231

5.147 Vitruvian Biomedical Inc Company Overview 232

5.147.1 Vitruvian Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 232

5.148 Washington University in St Louis Company Overview 233

5.148.1 Washington University in St Louis Pipeline Products & Ongoing Clinical Trials Overview 233

5.149 Washington University School of Medicine Company Overview 235

5.149.1 Washington University School of Medicine Pipeline Products & Ongoing Clinical Trials Overview 235

5.150 WellSIM Biomedical Technologies Inc Company Overview 238

5.150.1 WellSIM Biomedical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 238

5.151 Zoiray Technologies Inc. Company Overview 239

5.151.1 Zoiray Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 239

6 Alzheimer- Recent Developments 240

6.1 Nov 16, 2022: InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding 240

6.2 Nov 15, 2022: StageZero Life Sciences Announces Q3 2022 Financial Results and Operational Update 240

6.3 Nov 14, 2022: BioArctic receives new patent in the US for blood-brain barrier transport technology 243

6.4 Nov 14, 2022: ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights 243

6.5 Nov 11, 2022: StageZero to Hold Q3 2022 Operational and Financial Results Conference Call on Tuesday November 15, 2022 244

6.6 Nov 10, 2022: Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results 245

6.7 Nov 09, 2022: Keystone Bio Adds Significant Scientific Leadership with Appointment of Medical Advisor and New Scientific Advisory Board Members 246

6.8 Nov 03, 2022: Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022 247

6.9 Nov 01, 2022: Aspira Women’s Health to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10 248

6.10 Oct 31, 2022: Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member 248

6.11 Oct 26, 2022: URI neuroscientist receives $10.3 million grant for research on retinal scanning to detect early-stage Alzheimer’s 249

6.12 Oct 11, 2022: $9 million to fund study of ‘jumping genes’ in Alzheimer’s 250

6.13 Oct 06, 2022: Pfizer appoints Deb Mangone as Ireland country manager 251

6.14 Oct 04, 2022: Study of Alzheimer’s patients launched in bid to find early test 251

6.15 Sep 20, 2022: Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts 252

6.16 Sep 06, 2022: Labcorp to Speak at the Baird 2022 Global Healthcare Conference 253

6.17 Sep 06, 2022: Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 253

6.18 Aug 31, 2022: Bristol Myers Squibb to Participate in Citi’s 17th Annual BioPharma Conference 253

6.19 Aug 31, 2022: Pfizer lures first chief marketing officer from Verily 253

6.20 Aug 30, 2022: Cortechs.ai Awarded Million Dollar NIH Grant for Early Diagnosis of Alzheimer’s Disease Using Advanced Diffusion MRI Technique 253

6.21 Aug 24, 2022: Blood test detects Alzheimer’s in people with Down syndrome 254

6.22 Aug 19, 2022: Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 254

6.23 Aug 17, 2022: Mytide Therapeutics partners with Agilent to collaborate on automation solutions for Mytide’s next-generation manufacturing platform 255

6.24 Aug 16, 2022: StageZero Life Sciences Announces second quarter financial results for the three months ended June 30, 2022 256

6.25 Aug 12, 2022: StageZero to Hold Q2 2022 Operational and Financial Results Conference Call on Tuesday August 16, 2022 257

6.26 Aug 11, 2022: Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results 258

6.27 Aug 08, 2022: Research from Beacon Biosignals presented at Alzheimer’s Association International Conference 260

6.28 Aug 08, 2022: UNH awarded $2.8 million to develop robots to care for people with Alzheimer’s and Dementia 261

6.29 Aug 05, 2022: Researchers gain insights into the genetic and molecular machinery that predisposes individuals to Alzheimer’s Disease 261

6.30 Aug 05, 2022: Synaptogenix Announces Quarterly Report For the quarterly period ended June 30, 2022 262

6.31 Jul 28, 2022: AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update 264

6.32 Jul 28, 2022: Merck Announces Second-Quarter 2022 Financial Results 266

6.33 Jul 28, 2022: Labcorp Announces 2022 Second Quarter Results 270

6.34 Jul 28, 2022: Montefiore awarded $2.3 million to care for people with memory disorders in the Hudson Valley 274

6.35 Jul 22, 2022: ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022 274

6.36 Jul 12, 2022: Aspire & USF Pass $10M in ticket & donation revenue 276

6.37 Jul 05, 2022: ORYZON Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €20 Million Over 30 Months 276

6.38 Jun 24, 2022: Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts 277

6.39 Jun 15, 2022: Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A 277

6.40 Jun 09, 2022: Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 277

6.41 Jun 09, 2022: Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference 278

6.42 Jun 07, 2022: Molecular Stethoscope, announces new investment from the Alzheimer’s Drug Discovery Foundation 278

6.43 Jun 01, 2022: Agilent releases IVDR-compliant instruments, kits, and reagents for use in the European Union 278

6.44 May 26, 2022: Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference 279

6.45 May 25, 2022: Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 279

6.46 May 19, 2022: C2N introduces new test to aid Alzheimer’s diagnosis 279

6.47 May 17, 2022: Labcorp to Speak at the UBS 2022 Global Healthcare Conference 280

6.48 May 13, 2022: ProMIS Neurosciences Announces First Quarter 2022 Results 280

6.49 May 13, 2022: StageZero Life Sciences Announces annual and special meeting 283

6.50 May 05, 2022: ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2022 283

6.51 May 04, 2022: Luminex announces upcoming initial public offering 285

6.52 May 04, 2022: Labcorp to Webcast Its Annual Meeting of Shareholders 285

6.53 May 04, 2022: Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference 285

6.54 May 03, 2022: Pfizer Reports First quarter 2022 Results 285

6.55 Apr 28, 2022: Merck Announces First-Quarter 2022 Financial Results 290

6.56 Apr 28, 2022: AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update 294

6.57 Apr 27, 2022: Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer 295

6.58 Apr 26, 2022: New $4.2 Million NIH grant to discover novel markers of early Alzheimer’s Disease 296

6.59 Apr 20, 2022: BioArctic’s Invitation to presentation First Quarter Report for January – March 2022 on April 28 at

9.30 a.m. CET 297

6.60 Apr 20, 2022: Invitation to presentation of BioArctic’s First Quarter Report for January – March 2022 on April 28 at

9.30 a.m. CET 297

6.61 Apr 19, 2022: Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28 298

6.62 Apr 14, 2022: TauRx’s late-stage clinical trial reaches new milestone 298

6.63 Apr 06, 2022: StageZero Life Sciences announces corporate update 299

6.64 Mar 29, 2022: Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit 300

6.65 Mar 28, 2022: ORYZON Announces Appointment of Douglas V. Faller, MD, PhD as Global Chief Medical Officer and Continues its Expansion of US Corporate Activities 300

6.66 Mar 22, 2022: AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update 301

6.67 Mar 22, 2022: Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum 302

6.68 Mar 17, 2022: ProMIS Neurosciences Announces Fiscal Year 2021 Results 303

6.69 Mar 17, 2022: Plasma biomarker screening could improve accuracy, health equity in Alzheimer’s disease diagnosis 306

6.70 Mar 09, 2022: Bioasis to Attend and Present at Upcoming Industry Conference 307

6.71 Feb 28, 2022: Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 308

6.72 Feb 28, 2022: Feinstein Institutes’ studies show CTE-linked tau protein may contribute to psychosis in Alzheimer’s disease 308

6.73 Feb 24, 2022: Myriad Genetics Reports Fourth Quarter 2021 Results Provides Updates on Product Performance and Growth Initiatives 309

6.74 Feb 23, 2022: Amylyx Pharmaceuticals Expands Executive Team with Appointment of Gina M. Mazzariello as Chief Legal Officer and General Counsel 312

6.75 Feb 22, 2022: Agilent Reports First-Quarter Fiscal Year 2022 Financial Results 312

6.76 Feb 22, 2022: Aspira Women’s Health Expands Senior Leadership Team with Addition of Mr. Michael Newton as Head of Sales and Marketing 313

6.77 Feb 14, 2022: Myriad Genetics to Present at Two Upcoming Healthcare Conferences 314

6.78 Feb 09, 2022: Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 314

6.79 Feb 07, 2022: Altoida partners with GN Group to research and develop new cognitive assessment technology to detect mild cognitive impairment 314

6.80 Feb 03, 2022: Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results 315

6.81 Feb 03, 2022: ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board 319

6.82 Feb 01, 2022: Pfizer Announces New Chief Development Officer 319

6.83 Jan 27, 2022: Cognito Therapeutics and Providence Health Plan launch phase 3 study to evaluate disease-modifying therapeutic in mild cognitive impairment 320

6.84 Jan 27, 2022: New drug screening method answers why Alzheimer’s drugs fail, suggests new targets 321

6.85 Jan 25, 2022: Oxford BioDynamics announces Final Results 322

6.86 Jan 04, 2022: Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference 323

6.87 Jan 04, 2022: Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service 323

6.88 Jan 04, 2022: Labcorp to Speak Virtually at the 40th Annual J.P. Morgan Healthcare Conference 324

6.89 Dec 30, 2021: Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 324

6.90 Dec 17, 2021: Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4 2022 324

6.91 Dec 15, 2021: Alzheimer’s test provides much needed answers to patients and their families 325

6.92 Nov 29, 2021: Bioasis Announces Annual General Meeting Details 326

7 Appendix 327

7.1 Methodology 327

7.2 About GlobalData 330

7.3 Contact Us 330

7.4 Disclaimer 330

Table

Alzheimer – Pipeline Products by Stage of Development 24

Alzheimer – Pipeline Products by Territory 25

Alzheimer – Pipeline Products by Regulatory Path 26

Alzheimer – Pipeline Products by Estimated Approval Date 27

Alzheimer – Ongoing Clinical Trials 28

Alzheimer Companies – Pipeline Products by Stage of Development 29

Alzheimer – Pipeline Products by Stage of Development 35

5M Biomed LLC Pipeline Products & Ongoing Clinical Trials Overview 40

Liquid Biopsy Assay – Alzheimer’s Disease – Product Status 40

Liquid Biopsy Assay – Alzheimer’s Disease – Product Description 40

AC Immune SA Pipeline Products & Ongoing Clinical Trials Overview 41

Abeta-Based Diagnostic Test – Alzheimer´s Disease – Product Status 41

Abeta-Based Diagnostic Test – Alzheimer´s Disease – Product Description 41

pTau-Based Diagnostic Test – Alzheimer´s Disease – Product Status 42

pTau-Based Diagnostic Test – Alzheimer´s Disease – Product Description 42

Acobiom Pipeline Products & Ongoing Clinical Trials Overview 43

Companion Diagnostic Test – Alzheimer’s Disease – Product Status 43

Companion Diagnostic Test – Alzheimer’s Disease – Product Description 43

Diagnostic/Prognostic Assay – Alzheimer’s Disease – Product Status 44

Diagnostic/Prognostic Assay – Alzheimer’s Disease – Product Description 44

Acumen Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 45

Ultra-High Sensitivity Companion Diagnostic Assay – Product Status 45

Ultra-High Sensitivity Companion Diagnostic Assay – Product Description 45

Adlyfe Inc Pipeline Products & Ongoing Clinical Trials Overview 46

Diagnostic Assay – Alzheimer’s Disease – Product Status 46

Diagnostic Assay – Alzheimer’s Disease – Product Description 46

Admit Therapeutics SL Pipeline Products & Ongoing Clinical Trials Overview 47

Diagnostic Test – Alzheimer’s Disease – Product Status 47

Diagnostic Test – Alzheimer’s Disease – Product Description 47

ADx NeuroSciences NV Pipeline Products & Ongoing Clinical Trials Overview 48

ADDL’S Biomarker Test – Product Status 48

ADDL’S Biomarker Test – Product Description 49

Biomarker Assay – Amyloid Ratio High Sensitivity – Product Status 49

Biomarker Assay – Amyloid Ratio High Sensitivity – Product Description 49

Biomarker Assay – P-Tau Isoforms – Product Status 50

Biomarker Assay – P-Tau Isoforms – Product Description 50

Biomarker Assay – Tau Isoforms – Product Status 50

Biomarker Assay – Tau Isoforms – Product Description 50

Biomarker Test – O-TAU – Product Status 51

Biomarker Test – O-TAU – Product Description 51

Biomarker Test – SNAP 25 – Product Status 51

Biomarker Test – SNAP 25 – Product Description 51

Biomarker Test – Synuclein Oligo – Product Status 52

Biomarker Test – Synuclein Oligo – Product Description 52

Blood Based Amyloid Beta Biomarker Test – Product Status 52

Blood Based Amyloid Beta Biomarker Test – Product Description 52

GLOB. P3N Aß Biomarker Test – Product Status 53

GLOB. P3N Aß Biomarker Test – Product Description 53

NfL Test – Alzheimer’s Disease – Product Status 53

NfL Test – Alzheimer’s Disease – Product Description 54

Aelan Cell Technologies Pipeline Products & Ongoing Clinical Trials Overview 55

Diagnostic Blood Test – Alzheimer’s Disease – Product Status 55

Diagnostic Blood Test – Alzheimer’s Disease – Product Description 55

Agent Biotech Pipeline Products & Ongoing Clinical Trials Overview 56

Diagnostic Test – Alzheimer’s Disease – Product Status 56

Diagnostic Test – Alzheimer’s Disease – Product Description 56

Agent Biotech – Ongoing Clinical Trials Overview 57

Diagnostic Test – Alzheimer’s Disease – A Study of Blood-based Detection of Early-stage Alzheimer’s Using Multiomics and Machine Learning 58

Albert Ludwigs University of Freiburg Pipeline Products & Ongoing Clinical Trials Overview 59

Mitochondrial Preprotein Based Test – Alzheimer’s Disease – Product Status 59

Mitochondrial Preprotein Based Test – Alzheimer’s Disease – Product Description 59

Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 60

Diagnostic Assay – Alzheimer’s Disease – Product Status 60

Diagnostic Assay – Alzheimer’s Disease – Product Description 60

AltPep Corp Pipeline Products & Ongoing Clinical Trials Overview 61

SOBA-AD Assay – Product Status 61

SOBA-AD Assay – Product Description 61

Alzheon Inc Pipeline Products & Ongoing Clinical Trials Overview 62

Diagnostic Assay – Alzheimer’s Disease – Product Status 62

Diagnostic Assay – Alzheimer’s Disease – Product Description 62

Alzhyme Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

Diagnostic Test – Alzheimer’s Disease – Product Status 63

Diagnostic Test – Alzheimer’s Disease – Product Description 63

Alzinova AB Pipeline Products & Ongoing Clinical Trials Overview 64

ALZ-201-Based Diagnostic Test – Product Status 64

ALZ-201-Based Diagnostic Test – Product Description 64

Amarantus Bioscience Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 65

NuroPro – Alzheimer’s Disease – Product Status 65

NuroPro – Alzheimer’s Disease – Product Description 65

Amarantus Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 66

Georgetown Assay – Alzheimer’s Disease-Exosomes – Product Status 66

Georgetown Assay – Alzheimer’s Disease-Exosomes – Product Description 66

Ambergen Inc Pipeline Products & Ongoing Clinical Trials Overview 67

PC-PURE Immunoassay – Alzheimer’s Disease – Product Status 67

PC-PURE Immunoassay – Alzheimer’s Disease – Product Description 67

Amco International Manufacturing Inc. Pipeline Products & Ongoing Clinical Trials Overview 68

Georgetown Assay – Alzheimer’s Disease-Lipids – Product Status 68

Georgetown Assay – Alzheimer’s Disease-Lipids – Product Description 68

Amoneta Diagnostics SAS Pipeline Products & Ongoing Clinical Trials Overview 69

ADDIA Diagnostic Kit – Alzheimer’s Disease – Product Status 69

ADDIA Diagnostic Kit – Alzheimer’s Disease – Product Description 69

Amprion Inc Pipeline Products & Ongoing Clinical Trials Overview 70

Diagnostic Assay – Alzheimer’s Disease – Product Status 70

Diagnostic Assay – Alzheimer’s Disease – Product Description 70

Applied NeuroSolutions, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 71

P-Tau 231 Test – Product Status 71

P-Tau 231 Test – Product Description 71

Arkley Biotek LLC Pipeline Products & Ongoing Clinical Trials Overview 72

Blood Test – Alzheimer’s Disease – Product Status 72

Blood Test – Alzheimer’s Disease – Product Description 72

Ascent Bio-Nano Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 73

Acoustofluidic Device – Alzheimer’s Disease – Product Status 73

Acoustofluidic Device – Alzheimer’s Disease – Product Description 73

attyloid GmbH Pipeline Products & Ongoing Clinical Trials Overview 74

sFIDA – Product Status 74

sFIDA – Product Description 74

Banyan Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 75

Diagnostic Assay – Alzheimer’s Disease – Product Status 75

Diagnostic Assay – Alzheimer’s Disease – Product Description 75

Beaumont Health System Pipeline Products & Ongoing Clinical Trials Overview 76

AI-Based Blood Test – Alzheimer’s Disease – Product Status 76

AI-Based Blood Test – Alzheimer’s Disease – Product Description 76

BioArctic AB Pipeline Products & Ongoing Clinical Trials Overview 77

Diagnostic Test – Alzheimer’s Disease – Product Status 77

Diagnostic Test – Alzheimer’s Disease – Product Description 77

Bioasis Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 78

Cognitest – Product Status 78

Cognitest – Product Description 78

Biocross SL Pipeline Products & Ongoing Clinical Trials Overview 79

e4Quant Plus Test – Product Status 79

e4Quant Plus Test – Product Description 79

e4Quant Test – Product Status 80

e4Quant Test – Product Description 80

e4Risk Test – Product Status 80

e4Risk Test – Product Description 81

Biocross SL – Ongoing Clinical Trials Overview 82

e4Risk Test – Study of the Predictive Markers and the Pathophysiological Mechanisms of Alzheimer’s Disease: Transverse and Longitudinal Approach in Anatomical and Functional Multimodal Imaging 83

Biois Corp Pipeline Products & Ongoing Clinical Trials Overview 84

AptaSign – Alzheimer’s Disease – Product Status 84

AptaSign – Alzheimer’s Disease – Product Description 84

Biomedical Development Corp Pipeline Products & Ongoing Clinical Trials Overview 85

Vestibular – Topographical Memory Diagnostic Test – Product Status 85

Vestibular – Topographical Memory Diagnostic Test – Product Description 85

BioSystems International Pipeline Products & Ongoing Clinical Trials Overview 86

Diagnostic Test – Alzheimer’s Disease – Product Status 86

Diagnostic Test – Alzheimer’s Disease – Product Description 86

Boston University Medical Campus Pipeline Products & Ongoing Clinical Trials Overview 87

Diagnostic Test – Alzheimer’s Disease – Product Status 87

Diagnostic Test – Alzheimer’s Disease – Product Description 87

Brigham and Women’s Hospital Pipeline Products & Ongoing Clinical Trials Overview 88

NT1 Assay – Product Status 88

NT1 Assay – Product Description 88

C2N Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 89

Multi-Analyte Combination Assay – Product Status 89

Multi-Analyte Combination Assay – Product Description 89

p-tau217 Blood Test – Product Status 90

p-tau217 Blood Test – Product Description 90

C2N Diagnostics LLC – Ongoing Clinical Trials Overview 91

p-tau217 Blood Test – The Swedish Biofinder 2 Study 92

Calviri Inc Pipeline Products & Ongoing Clinical Trials Overview 93

Immunosignaturing Test – Alzheimer’s Disease – Product Status 93

Immunosignaturing Test – Alzheimer’s Disease – Product Description 93

Cassava Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 94

SavaDx – Product Status 94

SavaDx – Product Description 94

Cassava Sciences Inc – Ongoing Clinical Trials Overview 95

SavaDx – Validation/Disease Specificity Study of SavaDx for the Detection of Alzheimer’s Disease 96

Cayman Chemical Co Pipeline Products & Ongoing Clinical Trials Overview 97

Diagnostic Assay Kit – Alzheimer’s Disease – Product Status 97

Diagnostic Assay Kit – Alzheimer’s Disease – Product Description 97

Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 98

Companion Diagnostic Test – Alzheimer’s Disease – Product Status 98

Companion Diagnostic Test – Alzheimer’s Disease – Product Description 98

Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 99

Blood-Based Diagnostic Test – Alzheimer’s Disease – Product Status 99

Blood-Based Diagnostic Test – Alzheimer’s Disease – Product Description 99

Cognext Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 100

NPTX2 ELISA Assay – Alzheimer’s Disease – Product Status 100

NPTX2 ELISA Assay – Alzheimer’s Disease – Product Description 100

Columbia University Pipeline Products & Ongoing Clinical Trials Overview 101

Diagnostic Test – Alzheimer’s Disease – Product Status 101

Diagnostic Test – Alzheimer’s Disease – Product Description 101

Cx Precision Medicine Inc Pipeline Products & Ongoing Clinical Trials Overview 102

Alzheimer’s Disease Rule-Out Test – Product Status 102

Alzheimer’s Disease Rule-Out Test – Product Description 102

Alzheimer’s Therapeutic Matching Test – Product Status 103

Alzheimer’s Therapeutic Matching Test – Product Description 103

Amyloid Test – Product Status 103

Amyloid Test – Product Description 104

Confirmatory AD Test – Product Status 104

Confirmatory AD Test – Product Description 104

Cymedx Pipeline Products & Ongoing Clinical Trials Overview 105

Diagnostic Assay – Alzheimer’s Disease – Product Status 105

Diagnostic Assay – Alzheimer’s Disease – Product Description 105

Cytox Ltd Pipeline Products & Ongoing Clinical Trials Overview 106

ADpredict Screening Test – Product Status 106

ADpredict Screening Test – Product Description 106

genoSCORE – Product Status 107

genoSCORE – Product Description 107

genoTOR – Product Status 107

genoTOR – Product Description 108

Diadem SRL Pipeline Products & Ongoing Clinical Trials Overview 109

AlzoSure Confirm – Product Status 109

AlzoSure Confirm – Product Description 109

Alzosure Predict – Product Status 110

Alzosure Predict – Product Description 110

DiamiR LLC Pipeline Products & Ongoing Clinical Trials Overview 111

CogniMIR – Product Status 111

CogniMIR – Product Description 111

DiaPat GmbH Pipeline Products & Ongoing Clinical Trials Overview 112

DiaPat – Alzheimer’s Disease Test – Product Status 112

DiaPat – Alzheimer’s Disease Test – Product Description 112

Durin Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 113

Diagnostic Test – Alzheimer’s Disease – Product Status 113

Diagnostic Test – Alzheimer’s Disease – Product Description 113

Early Alzheimer’s Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 114

Diagnostic Tool – Alzheimer’s Disease – Product Status 114

Diagnostic Tool – Alzheimer’s Disease – Product Description 114

Emory University Pipeline Products & Ongoing Clinical Trials Overview 115

Diagnostic Test – Alzheimer’s Disease – Product Status 115

Diagnostic Test – Alzheimer’s Disease – Product Description 115

Eurobio Scientific SA Pipeline Products & Ongoing Clinical Trials Overview 116

EHT Dx23 – Product Status 116

EHT Dx23 – Product Description 116

Florida Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 117

Diagnostic Test – Alzheimer’s Disease – Product Status 117

Diagnostic Test – Alzheimer’s Disease – Product Description 117

French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 118

HTRF Test – Alzheimer Disease – Product Status 118

HTRF Test – Alzheimer Disease – Product Description 118

Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 119

Lumipulse G – Total TAU – Product Status 119

Lumipulse G – Total TAU – Product Description 119

Lumipulse G ß-Amyloid Ratio (1-42/1-40) – Product Status 120

Lumipulse G ß-Amyloid Ratio (1-42/1-40) – Product Description 120

Lumipulse G1200 – ß-amyloid 1-42 – Product Status 120

Lumipulse G1200 – ß-amyloid 1-42 – Product Description 121

GenoScreen SAS Pipeline Products & Ongoing Clinical Trials Overview 122

Diagnostic Test – Alzheimer’s Disease – Product Status 122

Diagnostic Test – Alzheimer’s Disease – Product Description 122

Ghent University Pipeline Products & Ongoing Clinical Trials Overview 123

Cerebrospinal Fluid Test – Alzheimer’s Disease – Product Status 123

Cerebrospinal Fluid Test – Alzheimer’s Disease – Product Description 123

IBM Research-Australia Pipeline Products & Ongoing Clinical Trials Overview 124

Blood Test – Alzheimer’s Disease – Product Status 124

Blood Test – Alzheimer’s Disease – Product Description 124

ICDD-sas Pipeline Products & Ongoing Clinical Trials Overview 125

ADFlag – Product Status 125

ADFlag – Product Description 125

ADselect – Product Status 126

ADselect – Product Description 126

Inbiomed Pipeline Products & Ongoing Clinical Trials Overview 127

Ubiquitin And SUMO Traps Assay – Alzheimer’s Disease – Product Status 127

Ubiquitin And SUMO Traps Assay – Alzheimer’s Disease – Product Description 127

Innovative Health Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 128

IHD-Amy Blood Test – Alzheimer’s Disease – Product Status 128

IHD-Amy Blood Test – Alzheimer’s Disease – Product Description 128

Inscopix Inc Pipeline Products & Ongoing Clinical Trials Overview 129

Alzheimer’s Disease Assay – Product Status 129

Alzheimer’s Disease Assay – Product Description 129

Instituto de Estructura de la Materia Pipeline Products & Ongoing Clinical Trials Overview 130

Blood-Based Diagnostic Test – Alzheimer’s Disease – Product Status 130

Blood-Based Diagnostic Test – Alzheimer’s Disease – Product Description 130

Integrated Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 131

Multiplexed Proteomic Assay – Alzheimer’s Disease – Product Status 131

Multiplexed Proteomic Assay – Alzheimer’s Disease – Product Description 131

Intelligent OMICS Ltd Pipeline Products & Ongoing Clinical Trials Overview 132

Biomarker Assay – Alzheimer’s Disease – Product Status 132

Biomarker Assay – Alzheimer’s Disease – Product Description 132

Janssen Pharmaceutica NV Pipeline Products & Ongoing Clinical Trials Overview 133

Diagnostic Biosignatures – Alzheimer’s Disease – Product Status 133

Diagnostic Biosignatures – Alzheimer’s Disease – Product Description 133

Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 134

BACE1 Diagnostic Assay – Product Status 134

BACE1 Diagnostic Assay – Product Description 134

Johns Hopkins University School of Medicine Pipeline Products & Ongoing Clinical Trials Overview 135

NPTX2 Biomarker Assay – Alzheimer’s Disease – Product Status 135

NPTX2 Biomarker Assay – Alzheimer’s Disease – Product Description 135

KineMed Inc Pipeline Products & Ongoing Clinical Trials Overview 136

Diagnostic Assay – Alzheimer’s Disease – Product Status 136

Diagnostic Assay – Alzheimer’s Disease – Product Description 136

King’s College London Pipeline Products & Ongoing Clinical Trials Overview 137

Monitoring Assay – Alzheimer’s Disease – Product Status 137

Monitoring Assay – Alzheimer’s Disease – Product Description 137

Lund University Pipeline Products & Ongoing Clinical Trials Overview 138

Blood Test – Alzheimer’s Disease – Product Status 138

Blood Test – Alzheimer’s Disease – Product Description 138

P-tau181 Test – Product Status 139

P-tau181 Test – Product Description 139

McGill University Health Center Pipeline Products & Ongoing Clinical Trials Overview 140

Diagnostic Test – Alzheimer’s Disease – Product Status 140

Diagnostic Test – Alzheimer’s Disease – Product Description 140

Medifron DBT Inc Pipeline Products & Ongoing Clinical Trials Overview 141

Next Generation Diagnostic Test – Alzhemier’s Disease – Product Status 141

Next Generation Diagnostic Test – Alzhemier’s Disease – Product Description 141

Memory Dx LLC Pipeline Products & Ongoing Clinical Trials Overview 142

REDx Test – Product Status 142

REDx Test – Product Description 142

Meso Scale Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 143

Biomarker Assay – Alzheimer’s Disease – Product Status 143

Biomarker Assay – Alzheimer’s Disease – Product Description 143

Metabolon Inc Pipeline Products & Ongoing Clinical Trials Overview 144

Diagnostic Test – Alzheimer’s Disease – Product Status 144

Diagnostic Test – Alzheimer’s Disease – Product Description 144

Michigan State University Pipeline Products & Ongoing Clinical Trials Overview 145

Diagnostic Test – Alzheimer’s Disease – Product Status 145

Diagnostic Test – Alzheimer’s Disease – Product Description 145

MYND Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 146

Diagnostic Test – Alzheimer’s Disease – Product Status 146

Diagnostic Test – Alzheimer’s Disease – Product Description 146

Myriad RBM Inc Pipeline Products & Ongoing Clinical Trials Overview 147

Diagnostic Test – Alzheimer’s Disease – Product Status 147

Diagnostic Test – Alzheimer’s Disease – Product Description 147

NanoSomiX Inc Pipeline Products & Ongoing Clinical Trials Overview 148

Diagnostic Panel – Alzheimer’s Disease – Product Status 148

Diagnostic Panel – Alzheimer’s Disease – Product Description 148

Exosome-based Blood Test For p-tau – Product Status 149

Exosome-based Blood Test For p-tau – Product Description 149

Nanosphere Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 150

Ultra-Sensitive Assay – Alzheimer’s Disease – Product Status 150

Ultra-Sensitive Assay – Alzheimer’s Disease – Product Description 150

National Research Foundation of Korea Pipeline Products & Ongoing Clinical Trials Overview 151

Carbon Nanotube Sensor – Alzheimer’s Disease – Product Status 151

Carbon Nanotube Sensor – Alzheimer’s Disease – Product Description 151

National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 152

Amplified Plasmonic Exosome Test – Product Status 152

Amplified Plasmonic Exosome Test – Product Description 152

Navotavo Inc Pipeline Products & Ongoing Clinical Trials Overview 153

BrainWatcher – Product Status 153

BrainWatcher – Product Description 153

Nel ASA Pipeline Products & Ongoing Clinical Trials Overview 154

ADtect PLUS – Product Status 154

ADtect PLUS – Product Description 154

MCItect ULTRA – Product Status 155

MCItect ULTRA – Product Description 155

NeoNeuro SAS Pipeline Products & Ongoing Clinical Trials Overview 156

Aptamarker AD – Product Status 156

Aptamarker AD – Product Description 156

Neuro Bio Ltd Pipeline Products & Ongoing Clinical Trials Overview 157

Companion Diagnostic Test – Alzheimer’s Disease – Product Status 157

Companion Diagnostic Test – Alzheimer’s Disease – Product Description 157

NeuroQuest Ltd Pipeline Products & Ongoing Clinical Trials Overview 158

Definitive Diagnostic Test – Alzheimer’s Disease – Product Status 158

Definitive Diagnostic Test – Alzheimer’s Disease – Product Description 158

NeuroVision Imaging LLC Pipeline Products & Ongoing Clinical Trials Overview 159

Blood-Based Screening Test – Alzheimer’s Disease – Product Status 159

Blood-Based Screening Test – Alzheimer’s Disease – Product Description 159

Newcastle University Pipeline Products & Ongoing Clinical Trials Overview 160

Olfactory Diagnostic Test – Alzheimer’s Disease – Product Status 160

Olfactory Diagnostic Test – Alzheimer’s Disease – Product Description 160

Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 161

NBT Diagnostic Test – Alzheimer’s Disease – Product Status 161

NBT Diagnostic Test – Alzheimer’s Disease – Product Description 161

Numares AG Pipeline Products & Ongoing Clinical Trials Overview 162

Axinon Test – Alzheimer’s Disease – Product Status 162

Axinon Test – Alzheimer’s Disease – Product Description 162

Oligomerix inc Pipeline Products & Ongoing Clinical Trials Overview 163

Drug Screening Assay – Alzheimer’s Disease – Product Status 163

Drug Screening Assay – Alzheimer’s Disease – Product Description 163

Orasi Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 164

Synchronous Neural Interaction Test – Alzheimer’s Disease – Product Status 164

Synchronous Neural Interaction Test – Alzheimer’s Disease – Product Description 164

Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview 165

Diagnostic Assay – Alzheimer’s Disease – Product Status 165

Diagnostic Assay – Alzheimer’s Disease – Product Description 165

ORY-2001 Companion Diagnostic Assay – Alzheimer’s Disease – Product Status 166

ORY-2001 Companion Diagnostic Assay – Alzheimer’s Disease – Product Description 166

Peri Rx Inc Pipeline Products & Ongoing Clinical Trials Overview 167

Saliva Test – Alzheimer’s Disease – Product Status 167

Saliva Test – Alzheimer’s Disease – Product Description 167

Pre Diagnostics AS Pipeline Products & Ongoing Clinical Trials Overview 168

PreDx – Alzheimer’s Disease – Product Status 168

PreDx – Alzheimer’s Disease – Product Description 168

Predemtec GmbH Pipeline Products & Ongoing Clinical Trials Overview 169

Predemtec DX – Product Status 169

Predemtec DX – Product Description 169

ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 170

Companion Diagnostic Test – Alzheimer’s Disease – Product Status 170

Companion Diagnostic Test – Alzheimer’s Disease – Product Description 170

NfL Test – Alzheimer’s Disease – Product Status 171

NfL Test – Alzheimer’s Disease – Product Description 171

P-tau181 Test – Alzheimer’s Disease – Product Status 171

P-tau181 Test – Alzheimer’s Disease – Product Description 172

Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 173

Biomarker Diagnostic Test – Alzheimer’s Disease – Product Status 173

Biomarker Diagnostic Test – Alzheimer’s Disease – Product Description 173

Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 174

Diagnostic Assay – Alzheimer’s Disease – Product Status 174

Diagnostic Assay – Alzheimer’s Disease – Product Description 174

Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 175

10 Protein MCI/AD Panel – Product Status 175

10 Protein MCI/AD Panel – Product Description 175

Alzheimer’s CSF 3-Plex Assay – Product Status 176

Alzheimer’s CSF 3-Plex Assay – Product Description 176

Diagnostic Assay – Alzheimer’s Disease (CSF) – Product Status 176

Diagnostic Assay – Alzheimer’s Disease (CSF) – Product Description 177

Proteomics International Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview 178

Diagnostic Test – Alzheimer’s Disease – Product Status 178

Diagnostic Test – Alzheimer’s Disease – Product Description 178

Quanterix Corp Pipeline Products & Ongoing Clinical Trials Overview 179

NeuroFilament Light Assay – Alzheimer’s Disease – Product Status 179

NeuroFilament Light Assay – Alzheimer’s Disease – Product Description 180

Tau-SIMOA Assay – ADRD – Product Status 180

Tau-SIMOA Assay – ADRD – Product Description 180

Tau-SIMOA Assay – Alzheimer’s Disease – Product Status 181

Tau-SIMOA Assay – Alzheimer’s Disease – Product Description 181

Ultrasensitive Test – Alzheimer’s Disease – Product Status 181

Ultrasensitive Test – Alzheimer’s Disease – Product Description 182

Redox Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 183

Diagnostic Assay – Alzheimer’s Disease – Product Status 183

Diagnostic Assay – Alzheimer’s Disease – Product Description 183

Roche Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 184

Blood Test – Alzheimer’s Disease – Product Status 184

Blood Test – Alzheimer’s Disease – Product Description 184

Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 185

Diagnostic Test – Alzheimer’s Disease – Product Status 185

Diagnostic Test – Alzheimer’s Disease – Product Description 185

Elecsys Amyloid Plasma Panel – Product Status 186

Elecsys Amyloid Plasma Panel – Product Description 186

Elecsys Phospho-Tau (181P) CSF – Product Status 186

Elecsys Phospho-Tau (181P) CSF – Product Description 187

Elecsys ß-Amyloid (1-42) CSF – Product Status 187

Elecsys ß-Amyloid (1-42) CSF – Product Description 187

Rockefeller University Pipeline Products & Ongoing Clinical Trials Overview 188

APP-C99 Biomarker Test – Alzheimer’s Disease – Product Status 188

APP-C99 Biomarker Test – Alzheimer’s Disease – Product Description 188

Ruhr-University Bochum Pipeline Products & Ongoing Clinical Trials Overview 189

Blood Test – Alzheimer’s disease – Product Status 189

Blood Test – Alzheimer’s disease – Product Description 189

Scanogen Inc Pipeline Products & Ongoing Clinical Trials Overview 190

Diagnostic Assay – Alzheimer’s Disease – Product Status 190

Diagnostic Assay – Alzheimer’s Disease – Product Description 190

Scout Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 191

Diagnostic Test – Alzheimer’s Disease – Product Status 191

Diagnostic Test – Alzheimer’s Disease – Product Description 191

Seer Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 192

Diagnostic Test – Alzheimer’s Disease – Product Status 192

Diagnostic Test – Alzheimer’s Disease – Product Description 192

Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview 193

Amyloid Beta 1-42 Based Alzheimer’s Test – Product Status 193

Amyloid Beta 1-42 Based Alzheimer’s Test – Product Description 193

Tau Biomarker Based Alzheimer’s Test – Product Status 194

Tau Biomarker Based Alzheimer’s Test – Product Description 194

Spanish National Research Council Pipeline Products & Ongoing Clinical Trials Overview 195

Diagnostic Assay – Alzheimer’s Disease – Product Status 195

Diagnostic Assay – Alzheimer’s Disease – Product Description 195

StageZero Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 196

Biomarker Diagnostic Test – Alzheimer’s Disease – Product Status 196

Biomarker Diagnostic Test – Alzheimer’s Disease – Product Description 196

Sugentech Inc Pipeline Products & Ongoing Clinical Trials Overview 197

Diagnostic Test – Alzheimer’s Disease – Product Status 197

Diagnostic Test – Alzheimer’s Disease – Product Description 197

Synaptogenix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 198

Diagnostic Assay – Alzheimer’s Disease – Product Status 198

Diagnostic Assay – Alzheimer’s Disease – Product Description 198

TauRx Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview 199

Diagnostic Test – Alzheimer’s Disease – Product Status 199

Diagnostic Test – Alzheimer’s Disease – Product Description 199

Telo Genomics Corp Pipeline Products & Ongoing Clinical Trials Overview 200

3D Telo-AD Test – Product Status 200

3D Telo-AD Test – Product Description 200

The Florey Institute of Neuroscience and Mental Health Pipeline Products & Ongoing Clinical Trials Overview 201

Companion Diagnostic Test – Alzheimer’s Disease – Product Status 201

Companion Diagnostic Test – Alzheimer’s Disease – Product Description 201

The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 202

Blood Test – Alzheimer’s Disease – Product Status 202

Blood Test – Alzheimer’s Disease – Product Description 202

The University of Nottingham Pipeline Products & Ongoing Clinical Trials Overview 203

Early Warning Test – Alzheimer’s Disease – Product Status 203

Early Warning Test – Alzheimer’s Disease – Product Description 203

Todos Medical Pipeline Products & Ongoing Clinical Trials Overview 204

LymPro Test – Product Status 204

LymPro Test – Product Description 204

Todos Medical – Ongoing Clinical Trials Overview 205

LymPro Test – A Study to Evaluate the Relationship Between LymPro Test with Amyloid PET Imaging in Mild Cognitive Impairment and Dementia Patients 206

TopoGEN Inc Pipeline Products & Ongoing Clinical Trials Overview 207

Peripheral Blood Biomarker Assay – Alzheimer’s Disease – Product Status 207

Peripheral Blood Biomarker Assay – Alzheimer’s Disease – Product Description 207

Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 208

Diagnostic Test – Alzheimer’s Disease – Product Status 208

Diagnostic Test – Alzheimer’s Disease – Product Description 208

University of Calgary Pipeline Products & Ongoing Clinical Trials Overview 209

Blood Test – Alzheimer’s Disease – Product Status 209

Blood Test – Alzheimer’s Disease – Product Description 209

University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 210

ptau181 Test – Alzheimer’s Disease – Product Status 210

ptau181 Test – Alzheimer’s Disease – Product Description 210

University of Chicago Pipeline Products & Ongoing Clinical Trials Overview 211

EdNd Diagnostic Kit – Alzheimer’s Disease – Product Status 211

EdNd Diagnostic Kit – Alzheimer’s Disease – Product Description 211

University of Georgia Pipeline Products & Ongoing Clinical Trials Overview 212

Diagnostic Assay – Alzheimer’s Disease – Product Status 212

Diagnostic Assay – Alzheimer’s Disease – Product Description 212

University of Gottingen Pipeline Products & Ongoing Clinical Trials Overview 213

Diagnostic Assay – Alzheimer’s Disease – Product Status 213

Diagnostic Assay – Alzheimer’s Disease – Product Description 213

Pyro-Glu-Abeta Peptides Based Diagnostic Assay – Product Status 214

Pyro-Glu-Abeta Peptides Based Diagnostic Assay – Product Description 214

University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 215

Alzheimer’s Disease Diagnostic Test – Product Status 215

Alzheimer’s Disease Diagnostic Test – Product Description 215

Diagnostic Test – Alzheimer’s Disease – Product Status 216

Diagnostic Test – Alzheimer’s Disease – Product Description 216

University of Luxembourg Pipeline Products & Ongoing Clinical Trials Overview 217

Phenotype Assay – Alzheimer’s Disease – Product Status 217

Phenotype Assay – Alzheimer’s Disease – Product Description 217

University of Maryland Baltimore Pipeline Products & Ongoing Clinical Trials Overview 218

Diagnostic Assay – Alzheimer’s Disease – Product Status 218

Diagnostic Assay – Alzheimer’s Disease – Product Description 218

University of Melbourne Pipeline Products & Ongoing Clinical Trials Overview 219

Blood Test – Alzheimer’s Disease – Product Status 219

Blood Test – Alzheimer’s Disease – Product Description 219

University of Oxford Pipeline Products & Ongoing Clinical Trials Overview 220

Blood Based Diagnostic Test – Alzheimer’s Disease – Product Status 220

Blood Based Diagnostic Test – Alzheimer’s Disease – Product Description 220

University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 221

Prognostic Test – Alzheimer’s Disease – Product Status 221

Prognostic Test – Alzheimer’s Disease – Product Description 221

University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 222

Cell-Ba

Figures

Alzheimer – Pipeline Products by Stage of Development 24

Alzheimer – Pipeline Products by Territory 25

Alzheimer – Pipeline Products by Regulatory Path 26

Alzheimer – Pipeline Products by Estimated Approval Date 27

Alzheimer – Ongoing Clinical Trials 28

Frequently asked questions

Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update thematic reports
Currency USD
$4,000

Can be used by individual purchaser only

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update in real time.

  • Access a live Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.